NASDAQ:ICCC ImmuCell (ICCC) Stock Price, News & Analysis $3.58 -0.03 (-0.83%) (As of 11/1/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends About ImmuCell Stock (NASDAQ:ICCC) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get ImmuCell alerts:Sign Up Key Stats Today's Range$3.56▼$3.6550-Day Range$3.53▼$4.1452-Week Range$3.34▼$5.59Volume24,668 shsAverage Volume18,817 shsMarket Capitalization$28.04 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test, a quick on-farm diagnostic that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, a bivalent gel tube formulation. In addition, it is developing Re-Tain Drug Product, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.Read More… 625,000% Gain (Ad)Imagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here ImmuCell Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks13th Percentile Overall ScoreICCC MarketRank™: ImmuCell scored higher than 13% of companies evaluated by MarketBeat, and ranked 930th out of 975 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for ImmuCell.Read more about ImmuCell's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of ImmuCell is -6.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ImmuCell is -6.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioImmuCell has a P/B Ratio of 1.11. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about ImmuCell's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.18% of the float of ImmuCell has been sold short.Short Interest Ratio / Days to CoverImmuCell has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in ImmuCell has recently decreased by 29.91%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldImmuCell does not currently pay a dividend.Dividend GrowthImmuCell does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.18% of the float of ImmuCell has been sold short.Short Interest Ratio / Days to CoverImmuCell has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in ImmuCell has recently decreased by 29.91%, indicating that investor sentiment is improving significantly. News and Social Media2.2 / 5News SentimentN/A News SentimentImmuCell has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.41 average news sentiment score of Medical companies. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, ImmuCell insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.60% of the stock of ImmuCell is held by insiders.Percentage Held by InstitutionsOnly 13.47% of the stock of ImmuCell is held by institutions.Read more about ImmuCell's insider trading history. Receive ICCC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ImmuCell and its competitors with MarketBeat's FREE daily newsletter. Email Address ICCC Stock News HeadlinesImmuCell Announces Preliminary, Unaudited Sales Results for Q3 2024October 8, 2024 | markets.businessinsider.comImmuCell Announces Preliminary, Unaudited Sales Results for Q3 2024October 8, 2024 | globenewswire.com625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.November 2, 2024 | Crypto Swap Profits (Ad)ImmuCell Second Quarter 2024 Earnings: US$0.20 loss per share (vs US$0.18 loss in 2Q 2023)August 16, 2024 | finance.yahoo.comImmuCell Corporation (ICCC) Q2 2024 Earnings Call TranscriptAugust 16, 2024 | seekingalpha.comImmuCell Announces Unaudited Financial Results for the Quarter Ended June 30, 2024August 13, 2024 | globenewswire.comImmuCell Corporation (ICCC)July 30, 2024 | finance.yahoo.comImmuCell Corporation (ICCC) stock historical prices & data – Yahoo FinanceJuly 23, 2024 | nz.finance.yahoo.comSee More Headlines ICCC Stock Analysis - Frequently Asked Questions How have ICCC shares performed this year? ImmuCell's stock was trading at $5.09 at the beginning of the year. Since then, ICCC shares have decreased by 29.7% and is now trading at $3.58. View the best growth stocks for 2024 here. How were ImmuCell's earnings last quarter? ImmuCell Co. (NASDAQ:ICCC) issued its quarterly earnings results on Tuesday, August, 13th. The biotechnology company reported ($0.20) EPS for the quarter. The biotechnology company had revenue of $5.47 million for the quarter. ImmuCell had a negative trailing twelve-month return on equity of 16.35% and a negative net margin of 17.44%. How do I buy shares of ImmuCell? Shares of ICCC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of ImmuCell own? Based on aggregate information from My MarketBeat watchlists, some other companies that ImmuCell investors own include VBI Vaccines (VBIV), Sorrento Therapeutics (SRNE), Altimmune (ALT), Biocept (BIOC), ImmunoGen (IMGN), Novavax (NVAX) and Pfizer (PFE). Company Calendar Last Earnings8/13/2024Today11/02/2024Next Earnings (Estimated)11/11/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Diagnostic substances Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ICCC CUSIPN/A CIK811641 Webwww.immucell.com Phone(207) 878-2770Fax207-878-2117Employees75Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.53) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-5,780,000.00 Net Margins-17.44% Pretax Margin-17.42% Return on Equity-16.35% Return on Assets-9.35% Debt Debt-to-Equity Ratio0.42 Current Ratio2.37 Quick Ratio0.77 Sales & Book Value Annual Sales$23.22 million Price / Sales1.21 Cash FlowN/A Price / Cash FlowN/A Book Value$3.23 per share Price / Book1.11Miscellaneous Outstanding Shares7,833,000Free Float7,316,000Market Cap$28.04 million OptionableNot Optionable Beta0.56 Social Links 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report This page (NASDAQ:ICCC) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | SponsoredHe made 1,303,329 in 12 months after Biden won…Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredHow Will You Survive A Post Election Retirement Heist?The clock is ticking, and your life savings are in an extremely vulnerable position. We are a few days away...American Hartford Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ImmuCell Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share ImmuCell With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.